<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="113">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532294</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-DXP593-101</org_study_id>
    <nct_id>NCT04532294</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants</brief_title>
  <official_title>A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to investigate the safety and tolerability of BGB-DXP593&#xD;
      administered intravenously as a single dose in healthy participants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Actual">February 13, 2021</completion_date>
  <primary_completion_date type="Actual">February 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From the day of study drug administration until 30 days after dose (up to approximately 160 days)</time_frame>
    <description>A TEAE is defined as an adverse event (AE) that had an onset date or a worsening in severity from baseline on or after the administration of study drug and up to 30 days after the dose of study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Changes in Vital Signs and Electrocardiograms</measure>
    <time_frame>Up to approximately 160 days</time_frame>
    <description>Systolic and diastolic blood pressure, pulse rate, body temperature, and respiratory rate were measured. Descriptive statistics for ECG parameters (heart rate and QTcF interval) and changes from baseline were summarized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Changes in Laboratory Parameters</measure>
    <time_frame>Up to approximately 160 days</time_frame>
    <description>Clinical laboratory values were evaluated for each laboratory parameter as applicable including hematology, serum chemistry and urinalysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of BGB-DXP593</measure>
    <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of BGB-DXP593</measure>
    <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC From Time Zero to Time of Last Quantifiable Concentration (AUClast) of BGB-DXP593</measure>
    <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC From Time Zero to Day 29 (AUC0-29) of BGB-DXP593</measure>
    <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of BGB-DXP593</measure>
    <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half Life (t1/2) of BGB-DXP593</measure>
    <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of BGB-DXP593</measure>
    <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vz) of BGB-DXP593</measure>
    <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenic Response to BGB-DXP593 as Assessed by the Detection of Antidrug Antibodies (ADA)</measure>
    <time_frame>Up to approximately160 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>BGB-DXP593: Dose Level A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BGB-DXP593 10 mg/kg on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BGB-DXP593: Dose Level B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BGB-DXP593 30 mg/kg on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo to match (PTM) BGB-DXP593 on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB DXP593</intervention_name>
    <description>Administered intravenously (IV) as specified in the treatment arm</description>
    <arm_group_label>BGB-DXP593: Dose Level A</arm_group_label>
    <arm_group_label>BGB-DXP593: Dose Level B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match BGB-DXP593</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria :&#xD;
&#xD;
          1. Participants are in good general health as determined by the investigator or medically&#xD;
             qualified designee, based on a medical evaluation including medical history, physical&#xD;
             examination, laboratory tests and cardiac monitoring&#xD;
&#xD;
          2. Body weight ≥ 50 kg and body mass index (BMI) within the range 18 to 32 kg/m2&#xD;
             (inclusive) Note: BMI = weight [kg] / (height [m])&#xD;
&#xD;
          3. Negative serum IgG to the SARS-CoV-2&#xD;
&#xD;
          4. Negative for COVID-19 based on the nasopharyngeal or oropharyngeal swab with the&#xD;
             method of real-time reverse transcription-polymerase chain reaction (rRT-PCR)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,&#xD;
             endocrinological, hematological, or neurological disorders capable of significantly&#xD;
             altering the absorption, metabolism, or elimination of drugs, constituting a risk to&#xD;
             the participant when taking the study drug; or interfering with the interpretation of&#xD;
             data&#xD;
&#xD;
          2. Any history of a severe allergic reaction prior to enrollment that has a reasonable&#xD;
             risk of recurrence during the study&#xD;
&#xD;
          3. Have a medical history of SARS infection&#xD;
&#xD;
          4. Any acute fever disease or infections&#xD;
&#xD;
          5. Any chronic or clinically significant medical condition that, in the opinion of the&#xD;
             investigator, would jeopardize the safety or rights of the participant, including but&#xD;
             not limited to: diabetes mellitus type I, chronic hepatitis; or clinically significant&#xD;
             forms of: drug or alcohol abuse, asthma (except for childhood asthma), autoimmune&#xD;
             disease, psychiatric disorders, or heart disease&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q Pharm Pty Limited</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <results_first_submitted>January 19, 2022</results_first_submitted>
  <results_first_submitted_qc>January 19, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2022</results_first_posted>
  <last_update_submitted>January 19, 2022</last_update_submitted>
  <last_update_submitted_qc>January 19, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT04532294/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT04532294/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received a single intravenous dose of matching placebo</description>
        </group>
        <group group_id="P2">
          <title>BGB-DXP593 10 mg/kg</title>
          <description>Participants received a single 10 milligrams/kilogram (mg/kg) intravenous dose of BGB-DXP593</description>
        </group>
        <group group_id="P3">
          <title>BGB-DXP593 30 mg/kg</title>
          <description>Participants received a single 30 milligrams/kilogram (mg/kg) intravenous dose of BGB-DXP593</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participants Not Dosed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set (SAS) : Includes all participants who received the study drug or placebo</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received a single intravenous dose of matching placebo</description>
        </group>
        <group group_id="B2">
          <title>BGB-DXP593 10 mg/kg</title>
          <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
        </group>
        <group group_id="B3">
          <title>BGB-DXP593 30 mg/kg</title>
          <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.0" spread="13.64"/>
                    <measurement group_id="B2" value="34.2" spread="16.46"/>
                    <measurement group_id="B3" value="39.7" spread="14.81"/>
                    <measurement group_id="B4" value="35.4" spread="14.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
        <description>A TEAE is defined as an adverse event (AE) that had an onset date or a worsening in severity from baseline on or after the administration of study drug and up to 30 days after the dose of study drug</description>
        <time_frame>From the day of study drug administration until 30 days after dose (up to approximately 160 days)</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single intravenous dose of matching placebo</description>
          </group>
          <group group_id="O2">
            <title>BGB-DXP593 10 mg/kg</title>
            <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
          <group group_id="O3">
            <title>BGB-DXP593 30 mg/kg</title>
            <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</title>
          <description>A TEAE is defined as an adverse event (AE) that had an onset date or a worsening in severity from baseline on or after the administration of study drug and up to 30 days after the dose of study drug</description>
          <population>Safety analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with at least 1 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Relevant Changes in Vital Signs and Electrocardiograms</title>
        <description>Systolic and diastolic blood pressure, pulse rate, body temperature, and respiratory rate were measured. Descriptive statistics for ECG parameters (heart rate and QTcF interval) and changes from baseline were summarized</description>
        <time_frame>Up to approximately 160 days</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single intravenous dose of matching placebo</description>
          </group>
          <group group_id="O2">
            <title>BGB-DXP593 10 mg/kg</title>
            <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
          <group group_id="O3">
            <title>BGB-DXP593 30 mg/kg</title>
            <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Changes in Vital Signs and Electrocardiograms</title>
          <description>Systolic and diastolic blood pressure, pulse rate, body temperature, and respiratory rate were measured. Descriptive statistics for ECG parameters (heart rate and QTcF interval) and changes from baseline were summarized</description>
          <population>Safety analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with changes in vital signs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with changes in ECG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Relevant Changes in Laboratory Parameters</title>
        <description>Clinical laboratory values were evaluated for each laboratory parameter as applicable including hematology, serum chemistry and urinalysis.</description>
        <time_frame>Up to approximately 160 days</time_frame>
        <population>Safety analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received a single intravenous dose of matching placebo</description>
          </group>
          <group group_id="O2">
            <title>BGB-DXP593 10 mg/kg</title>
            <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
          <group group_id="O3">
            <title>BGB-DXP593 30 mg/kg</title>
            <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Changes in Laboratory Parameters</title>
          <description>Clinical laboratory values were evaluated for each laboratory parameter as applicable including hematology, serum chemistry and urinalysis.</description>
          <population>Safety analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of BGB-DXP593</title>
        <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set includes all the participants who received the study drug and had any measurable concentration of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>BGB-DXP593 10 mg/kg</title>
            <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
          <group group_id="O2">
            <title>BGB-DXP593 30 mg/kg</title>
            <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of BGB-DXP593</title>
          <population>Pharmacokinetic (PK) Analysis Set includes all the participants who received the study drug and had any measurable concentration of study drug.</population>
          <units>μg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255.3" lower_limit="213" upper_limit="328"/>
                    <measurement group_id="O2" value="667.0" lower_limit="511" upper_limit="787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of BGB-DXP593</title>
        <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>BGB-DXP593 10 mg/kg</title>
            <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
          <group group_id="O2">
            <title>BGB-DXP593 30 mg/kg</title>
            <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of BGB-DXP593</title>
          <population>PK Analysis Set</population>
          <units>day*μg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4168.8" lower_limit="3565" upper_limit="6188"/>
                    <measurement group_id="O2" value="12422.6" lower_limit="9095" upper_limit="15810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC From Time Zero to Time of Last Quantifiable Concentration (AUClast) of BGB-DXP593</title>
        <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>BGB-DXP593 10 mg/kg</title>
            <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
          <group group_id="O2">
            <title>BGB-DXP593 30 mg/kg</title>
            <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Time Zero to Time of Last Quantifiable Concentration (AUClast) of BGB-DXP593</title>
          <population>PK Analysis Set</population>
          <units>day*μg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3964.6" lower_limit="3388" upper_limit="5887"/>
                    <measurement group_id="O2" value="11434.2" lower_limit="8912" upper_limit="15334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC From Time Zero to Day 29 (AUC0-29) of BGB-DXP593</title>
        <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, and 29</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>BGB-DXP593 10 mg/kg</title>
            <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
          <group group_id="O2">
            <title>BGB-DXP593 30 mg/kg</title>
            <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Time Zero to Day 29 (AUC0-29) of BGB-DXP593</title>
          <population>PK Analysis Set</population>
          <units>day*μg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2368.4" lower_limit="2052" upper_limit="3489"/>
                    <measurement group_id="O2" value="6683.9" lower_limit="5919" upper_limit="9022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Plasma Concentration (Tmax) of BGB-DXP593</title>
        <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>BGB-DXP593 10 mg/kg</title>
            <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
          <group group_id="O2">
            <title>BGB-DXP593 30 mg/kg</title>
            <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Concentration (Tmax) of BGB-DXP593</title>
          <population>PK Analysis Set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" lower_limit="1.3" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.67" lower_limit="1.2" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half Life (t1/2) of BGB-DXP593</title>
        <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>BGB-DXP593 10 mg/kg</title>
            <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
          <group group_id="O2">
            <title>BGB-DXP593 30 mg/kg</title>
            <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half Life (t1/2) of BGB-DXP593</title>
          <population>PK Analysis Set</population>
          <units>Day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.60" lower_limit="20.4" upper_limit="32.1"/>
                    <measurement group_id="O2" value="25.77" lower_limit="20.7" upper_limit="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (CL) of BGB-DXP593</title>
        <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>BGB-DXP593 10 mg/kg</title>
            <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
          <group group_id="O2">
            <title>BGB-DXP593 30 mg/kg</title>
            <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (CL) of BGB-DXP593</title>
          <population>PK Analysis Set</population>
          <units>Liters/Day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.1" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.19" lower_limit="0.1" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (Vz) of BGB-DXP593</title>
        <time_frame>Day 1 (pre-dose, End of Infusion, 6 hrs. post-dose), Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57, 71, 85 and End of study visit (Up to approximately160 days)</time_frame>
        <population>PK Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>BGB-DXP593 10 mg/kg</title>
            <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
          <group group_id="O2">
            <title>BGB-DXP593 30 mg/kg</title>
            <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vz) of BGB-DXP593</title>
          <population>PK Analysis Set</population>
          <units>Liters</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.54" lower_limit="3.1" upper_limit="8.1"/>
                    <measurement group_id="O2" value="6.30" lower_limit="5.7" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenic Response to BGB-DXP593 as Assessed by the Detection of Antidrug Antibodies (ADA)</title>
        <time_frame>Up to approximately160 days</time_frame>
        <population>The ADA Analysis Set includes all the participants who received the study drug and in whom both baseline ADA and at least 1 postbaseline ADA results are available</population>
        <group_list>
          <group group_id="O1">
            <title>BGB-DXP593 10 mg/kg</title>
            <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
          <group group_id="O2">
            <title>BGB-DXP593 30 mg/kg</title>
            <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenic Response to BGB-DXP593 as Assessed by the Detection of Antidrug Antibodies (ADA)</title>
          <population>The ADA Analysis Set includes all the participants who received the study drug and in whom both baseline ADA and at least 1 postbaseline ADA results are available</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Induced ADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing antibody (NAb) Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the day of study drug administration until 30 days after dose (Up to approximately160 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received a single intravenous dose of matching placebo</description>
        </group>
        <group group_id="E2">
          <title>BGB-DXP593 10 mg/kg</title>
          <description>Participants received a single 10 mg/kg intravenous dose of BGB-DXP593</description>
        </group>
        <group group_id="E3">
          <title>BGB-DXP593 30 mg/kg</title>
          <description>Participants received a single 30 mg/kg intravenous dose of BGB-DXP593</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 24.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA) Version 24.0">Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Catheter site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Catheter site bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title vocab="MedDRA) Version 24.0">Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title vocab="MedDRA) Version 24.0">Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA) Version 24.0">Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title vocab="MedDRA) Version 24.0">Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Intermenstrual bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information &amp; may request a further delay to protect its IP rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>BeiGene</organization>
      <phone>+1-877-828-5568</phone>
      <email>clinicaltrials@beigene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

